Viyash Scientific Limited

BSE: 512529 NSE: VIYASH
Viyash Scientific Limited - chemicals in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L99999TS1985PLC196357 Incorporated 28 June 1985 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: VIYASH · BSE: 512529 Public Limited Company chemicals
Data last updated
Market Cap
₹9,188 Cr
VIYASH · NSE
Share Price
₹204.18
-1.83% today
Revenue
₹3,420 Cr
FY 2025-26 · +13.8% YoY
EBITDA
₹608 Cr
Margin 17.8%
Net Profit
₹203 Cr
FY 2025-26 · +1173.3% YoY
P/E (TTM)
42.1x
P/B 3.4x
ROE
8.3%
ROCE 12.1%
Debt / Equity
0.21
Interest cover 18.5x

About Viyash Scientific Limited

Data last updated:

Viyash Scientific Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the pharmaceuticals segment of the chemicals sector. It was incorporated on 28 June 1985 and has been in existence for over 41 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L99999TS1985PLC196357. Its GSTIN is 29AAACV1501G1ZP (Karnataka). The company holds 7 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 512529 and NSE: VIYASH.

The company has an authorised share capital of ₹886.15 Cr and a paid-up capital of ₹87.38 Cr. It was formerly known as Visistha Trades & Finance Limited and P.I. Drugs & Pharmaceuticals Limited. It is led by directors including Rajaram Narayanan (Whole-Time Director) and Srinivas Vasireddy (Whole-Time Director).

Its last annual general meeting (AGM) was held on 08 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Hyderabad, Telangana.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹3,420.31 Cr, a growth of 13.8% compared to the previous year. For the same year it recorded a net profit of ₹202.71 Cr (net margin 5.9%) and EBITDA of ₹608.32 Cr (EBITDA margin 17.8%). The net worth stands at ₹2,911.05 Cr (up 19.7% YoY). Total assets are valued at ₹3,798.93 Cr (up 12.3% YoY).

The company has about 399 employees on its provident fund (EPFO) records. Its group structure includes 7 subsidiaries.

As per MCA filings, the company has open charges of ₹792.53 Cr and satisfied charges of ₹1,664.02 Cr on record. Court records list 7 cases involving the company, including 5 filed by the company and 2 filed against it.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sequent.in.

Company details

CIN L99999TS1985PLC196357
Registration Number 196357
Incorporation Date 28 June 1985
ROC Hyderabad
Listing Status Listed - Listed on NSE (VIYASH); Listed on BSE (512529)
Company Status Active
Date of Last AGM 08 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Viyash Scientific has undergone 4 name changes throughout its history. The current legal name is Viyash Scientific Limited.

Company NameStatus
Viyash Scientific LimitedCurrent
Visistha Trades & Finance LimitedPrevious
P.I. Drugs & Pharmaceuticals LimitedPrevious
Visistha Trades And Finance LimitedPrevious

CIN history

Viyash Scientific has one previous CIN (Corporate Identification Number): L99999MH1985PLC036685. The current CIN is L99999TS1985PLC196357, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L99999TS1985PLC196357Current
L99999MH1985PLC036685Previous
Key People
Hari Babu Bodepudi Ceo Rajaram Narayanan Whole-Time Director Srinivas Vasireddy Whole-Time Director

Contact details

Viyash Scientific Limited's registered office is in Hyderabad, Telangana. Its website is sequent.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    sequent.in
  • Social Media
  • Registered Address
    3rd Floor Srivalli S Corporate Plot No. 290, Syn 33 34P To 39 Guttala Begumpet, Hyderabad, Telangana, India – 500033
  • Industry
    Chemicals, Pharmaceuticals, Medicinal Chemical & Botanical Products, Chemical Products

To see the full contact details of Viyash Scientific Limited, buy the company report.

Comprehensive company report
Viyash Scientific Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Viyash Scientific is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Viyash Scientific Limited, buy the company report.

Financials of Viyash Scientific Limited

FY 2025-26 filings available

Viyash Scientific Limited reported revenue of ₹3,420.31 Cr (up 13.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹3,420 Cr
+13.8% YoY
EBITDA
₹608 Cr
+102.0% YoY
Profit After Tax
₹203 Cr
+1173.3% YoY
Net Worth
₹2,911 Cr
+19.7% YoY
Total Assets
₹3,799 Cr
+12.3% YoY
Total Debt
₹490 Cr
-25.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,4203,0071,3701,4211,4131,3621,179
Revenue growth+13.8%+119.5%-3.6%+0.6%+3.8%+15.5%-
EBITDA60830129.26(52.84)109203170
EBITDA margin+17.8%+10.0%+2.1%-3.7%+7.7%+14.9%+14.4%
Profit before tax34913.18(54.65)(138)52.9413794.08
Net profit20315.92(27.18)(62.03)40.8399.6969.58
Net profit margin+5.9%+0.5%-2.0%-4.4%+2.9%+7.3%+5.9%
EPS (₹)4.060.93(1.44)(4.86)1.653.842.81
Balance sheet
Total assets3,7993,3821,2221,2151,1241,0631,153
Net worth2,9112,432657699692728687
Total debt490654488444365277343
Cash & bank27015769.8341.7559.2556.2075.83
Net working capital1,4581,037497478470386363
Cash flow
Cash from operations32334530.6016.8130.60115115
Cash from investing(84.12)(448)(5.92)(64.96)(94.10)9.65(72.27)
Cash from financing(123)87.04(1.44)32.2367.26(139)(42.75)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue946920858424792402391369
Revenue growth (YoY)+19.5%+129.0%+119.7%+15.0%+102.9%---
Other income8.3115.9213.982.156.841.665.844.51
EBITDA17818413453.9811845.9034.1934.78
EBITDA margin+18.8%+20.0%+15.7%+12.7%+14.8%+11.4%+8.7%+9.4%
Depreciation61.7760.4158.5315.4655.5916.1216.9817.10
Interest12.5114.5216.7513.5120.4315.1314.9514.29
Profit before tax11212573.0727.1648.3416.318.107.90
Tax33.1258.8624.557.5611.495.931.621.56
Net profit79.2966.3848.5219.6036.8510.386.486.34
EPS (₹)1.471.170.870.580.560.360.130.10
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3821,310169223220265227
Revenue growth+5.5%+677.6%-24.3%+1.4%-17.3%+16.8%-
EBITDA190126(32.92)(26.37)(0.75)32.7222.23
EBITDA margin+13.8%+9.7%-19.5%-11.8%-0.3%+12.3%+9.8%
Profit before tax11649.16(0.24)(9.76)15.6940.8822.80
Net profit10590.972.31(6.10)14.8032.8521.33
Net profit margin+7.6%+6.9%+1.4%-2.7%+6.7%+12.4%+9.4%
EPS (₹)1.742.340.02(0.24)0.601.290.86
Balance sheet
Total assets3,2403,1281,1361,0811,0601,037924
Net worth3,1892,9081,0871,0581,0411,030886
Total debt32.5420546.7720.2816.855.6635.07
Cash & bank35.0226.690.960.1812.890.743.72
Net working capital57344945.2833.3981.3953.8419.88
Cash flow
Cash from operations119188(26.94)37.759.362.3430.20
Cash from investing(107)(411)5.47(50.70)(4.25)16.55(17.69)
Cash from financing(7.06)19522.320.247.25(21.33)(10.71)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue35437234234.0332842.3336.2741.99
Revenue growth (YoY)+7.8%+780.0%+841.9%-19.0%+469.1%---
Other income14.5919.7516.2911.7512.9012.2711.8815.95
Total expenses30731031338.3728045.4041.0648.41
EBITDA47.1562.6929.08(4.34)48.20(3.07)(4.79)(6.42)
EBITDA margin+13.3%+16.8%+8.5%-12.8%+14.7%-7.3%-13.2%-15.3%
Depreciation32.4131.1631.202.2430.892.302.242.12
Interest1.442.533.560.836.020.991.171.00
Profit before tax27.8948.7510.614.3424.195.913.686.41
Tax6.9712.9410.691.266.891.680.872.15

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue946920858424792402391369
Revenue growth (YoY)+19.5%+129.0%+119.7%+15.0%+102.9%---
Other income8.3115.9213.982.156.841.665.844.51
EBITDA17818413453.9811845.9034.1934.78
EBITDA margin+18.8%+20.0%+15.7%+12.7%+14.8%+11.4%+8.7%+9.4%
Depreciation61.7760.4158.5315.4655.5916.1216.9817.10
Interest12.5114.5216.7513.5120.4315.1314.9514.29
Profit before tax11212573.0727.1648.3416.318.107.90
Tax33.1258.8624.557.5611.495.931.621.56
Net profit79.2966.3848.5219.6036.8510.386.486.34
EPS (₹)1.471.170.870.580.560.360.130.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,4203,0071,3701,4211,4131,3621,179
Revenue growth+13.8%+119.5%-3.6%+0.6%+3.8%+15.5%-
Other income43.5537.1725.726.3910.858.3610.09
Total expenses2,8122,7061,3401,4741,3031,1581,009
Employee cost566552251258231187165
EBITDA60830129.26(52.84)109203170
EBITDA margin+17.8%+10.0%+2.1%-3.7%+7.7%+14.9%+14.4%
Depreciation23423961.5455.6951.5450.6050.62
Interest69.2186.3748.0935.5215.7724.3835.71
Profit before tax34913.18(54.65)(138)52.9413794.08
Tax124(2.59)(25.03)(15.68)8.1732.1812.03
Net profit20315.92(27.18)(62.03)40.8399.6969.58
Net profit margin+5.9%+0.5%-2.0%-4.4%+2.9%+7.3%+5.9%
EPS (₹)4.060.93(1.44)(4.86)1.653.842.81
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital87.3750.0649.8949.8949.6749.6749.67
Reserves & surplus2,7312,382607649633678637
Shareholders' funds (net worth)2,9112,432657699692728687
Minority interest20413356.4050.4148.0148.6744.74
Secured loans342474307244208120243
Unsecured loans148180181199157157100
Total debt490654488444365277343
Total liabilities3,7993,3821,2221,2151,1241,0631,153
Assets
Gross block3,5223,277959940825753762
Net block2,1032,103592605564536577
Capital work in progress70.4643.4015.9355.2811.6330.7913.42
Investments0.070.093.510.0538.2382.59171
Inventories803682346346348264219
Sundry debtors1,045806336341329346319
Cash & bank balances27015769.8341.7559.2556.2075.83
Loans & advances13613756.6350.9545.2841.2449.95
Total current assets2,2541,783808780782708664
Total current liabilities797746311302312322301
Net working capital1,4581,037497478470386363
Total assets3,7993,3821,2221,2151,1241,0631,153
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash14015641.5757.5053.7468.1067.79
Net cash from operating activities32334530.6016.8130.60115115
Net cash from investing activities(84.12)(448)(5.92)(64.96)(94.10)9.65(72.27)
Net cash from financing activities(123)87.04(1.44)32.2367.26(139)(42.75)
Net change in cash115(15.88)23.24(15.92)3.75(14.35)0.31
Closing cash27015769.8341.7559.2556.2075.83
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.8%+119.5%-3.6%+0.6%+3.8%+15.5%-
EBITDA growth+102.0%+929.0%+155.4%-148.3%-46.2%+19.3%-
PBT growth+2548.1%+9998.0%+60.3%--61.3%+45.2%+59.8%
Net income growth+1173.3%+158.6%+56.2%-251.9%-59.0%+43.3%-
Revenue CAGR (3Y)+34.0%+28.6%+0.2%+6.4%+10.8%+17.1%+19.9%
EBITDA CAGR (3Y)-+40.1%-47.6%--4.3%+40.1%+61.5%
Profitability & leverage
Net income margin+6.6%+0.5%-2.2%-8.6%+3.2%+7.7%+7.0%
Return on capital employed+12.1%+6.9%+0.5%-3.5%+6.6%+14.6%+10.8%
Return on net worth+8.3%+0.5%-3.1%-9.0%+6.3%+14.0%+10.2%
Debt / equity0.210.370.690.580.450.440.48
Long-term debt / equity0.140.180.260.250.210.200.21
Interest cover18.47138.46-148.98-32.7327.2615.9729.83
Efficiency & per share
Fixed asset turnover1.011.421.441.611.791.801.68
Inventory turnover4.615.853.964.094.615.635.62
Debtors turnover3.695.274.054.244.184.103.95
EPS (₹)4.060.93(1.44)(4.86)1.653.842.81
Dividend per share (₹)0.000.000.000.000.000.500.00
Book value per share (₹)64.5297.1526.3228.0127.5029.3027.66
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue35437234234.0332842.3336.2741.99
Revenue growth (YoY)+7.8%+780.0%+841.9%-19.0%+469.1%---
Other income14.5919.7516.2911.7512.9012.2711.8815.95
Total expenses30731031338.3728045.4041.0648.41
EBITDA47.1562.6929.08(4.34)48.20(3.07)(4.79)(6.42)
EBITDA margin+13.3%+16.8%+8.5%-12.8%+14.7%-7.3%-13.2%-15.3%
Depreciation32.4131.1631.202.2430.892.302.242.12
Interest1.442.533.560.836.020.991.171.00
Profit before tax27.8948.7510.614.3424.195.913.686.41
Tax6.9712.9410.691.266.891.680.872.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3821,310169223220265227
Revenue growth+5.5%+677.6%-24.3%+1.4%-17.3%+16.8%-
Other income66.2672.5945.9828.2427.6419.9714.56
Total expenses1,1921,184201249220233205
Employee cost21421630.0536.6627.3822.4217.10
EBITDA190126(32.92)(26.37)(0.75)32.7222.23
EBITDA margin+13.8%+9.7%-19.5%-11.8%-0.3%+12.3%+9.8%
Depreciation1241258.949.129.599.138.95
Interest16.2125.144.362.511.612.685.04
Profit before tax11649.16(0.24)(9.76)15.6940.8822.80
Tax40.35(9.32)(0.86)(3.66)0.898.781.47
Net profit10590.972.31(6.10)14.8032.8521.33
Net profit margin+7.6%+6.9%+1.4%-2.7%+6.7%+12.4%+9.4%
EPS (₹)1.742.340.02(0.24)0.601.290.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital87.3750.0649.8949.8949.6749.6749.67
Reserves & surplus3,0092,8581,0371,008982980837
Shareholders' funds (net worth)3,1892,9081,0871,0581,0411,030886
Secured loans19.5716246.4619.1015.505.2235.07
Unsecured loans12.9742.550.311.181.350.440.00
Total debt32.5420546.7720.2816.855.6635.07
Total liabilities3,2403,1281,1361,0811,0601,037924
Assets
Gross block1,8601,81087.1510611210399.30
Net block1,1621,22042.5356.7266.9165.7869.41
Capital work in progress55.4234.405.142.201.404.343.72
Investments977968640633659685758
Inventories29327934.5447.9567.9945.7931.42
Sundry debtors55444544.7913.6552.4261.4440.79
Cash & bank balances35.0226.690.960.1812.890.743.72
Loans & advances80.2488.9716.3813.2112.4210.5317.00
Total current assets96283996.6774.9914611892.93
Total current liabilities39039151.3941.6064.3364.6673.05
Net working capital57344945.2833.3981.3953.8419.88
Total assets3,2403,1281,1361,0811,0601,037924
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash15.7943.150.0812.800.442.871.07
Net cash from operating activities119188(26.94)37.759.362.3430.20
Net cash from investing activities(107)(411)5.47(50.70)(4.25)16.55(17.69)
Net cash from financing activities(7.06)19522.320.247.25(21.33)(10.71)
Net change in cash5.18(27.36)0.84(12.71)12.36(2.44)1.81
Closing cash35.0226.690.960.1812.890.743.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.5%+677.6%-24.3%+1.4%-17.3%+16.8%-
EBITDA growth+50.5%+484.1%-24.8%-3416.0%-102.3%+47.2%-
PBT growth+136.4%+9998.0%+97.5%--61.6%+79.3%+267.2%
Net income growth+14.9%+3838.1%+137.9%-141.2%-55.0%+54.0%-
Revenue CAGR (3Y)+83.8%+81.4%-14.1%-0.7%+9.7%+35.8%+35.8%
Profitability & leverage
Net income margin+5.5%+4.5%+0.4%-2.7%+6.7%+12.1%+9.4%
Return on capital employed+4.9%+6.2%+0.5%-0.7%+1.7%+4.3%+2.8%
Return on net worth+3.0%+4.1%+0.2%-0.6%+1.4%+3.3%+2.2%
Debt / equity0.040.060.030.020.010.020.04
Long-term debt / equity0.020.020.000.000.000.010.02
Interest cover24.491,470.18-10.42-7.07-15.5711.3637.95
Efficiency & per share
Fixed asset turnover0.751.381.752.042.042.632.63
Inventory turnover4.848.374.093.843.866.888.01
Debtors turnover2.775.355.776.743.865.195.43
EPS (₹)1.742.340.02(0.24)0.601.290.86
Dividend per share (₹)0.000.000.000.000.000.500.00
Book value per share (₹)70.88116.2043.5942.4341.5541.4535.68

To see the full year-wise statements and ratios of Viyash Scientific Limited, buy the company report.

Board of directors and KMP of Viyash Scientific Limited

Viyash Scientific Limited currently reports 8 directors and 1 key managerial person. 42 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Revati Parag KastureDirector17 Dec 20241 Years 10 MonthsCurrent
Milind Shripad Sarwate
Also directs: Increate Value Advisors LLP, Increate Social Value Advisors & Resourcers LLP, Asian Paints Limited and 5 more
Director25 Aug 20206 Years 1 MonthsCurrent
Kamal Kishore Sharma
Also directs: Templecraft Realty LLP, Templeriviere Property LLP, Temple Wellness Ventures LLP and 4 more
Director25 Aug 20206 Years 1 MonthsCurrent
Anuj Vishnukumar Poddar
Also directs: Highway Roop Precision Technologies Limited, VLCC Limited
Director05 Sep 20251 Years 1 MonthsCurrent
Hari Babu BodepudiCeo16 Dec 20250 Years 10 MonthsCurrent
Rajaram Narayanan
Also directs: Alivira Animal Health Limited
Whole-Time Director11 Apr 20224 Years 6 MonthsCurrent
Showing 6 of 9 current directors and KMP. View all directors and KMP

Peer comparison

Viyash Scientific Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers, Animal Pharma), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Viyash Scientific Limitedthis company₹3,420.31 Cr (FY 2026)₹202.71 Cr5.9%13.8%399Hyderabad, Telangana, India
Aarti Pharmalabs Limited₹1,857.5 Cr (FY 2024)-5.0%Vapi, Gujarat, India
Morepen Laboratories Limited₹1,829.94 Cr (FY 2025)7.0%Himachal Pradesh, India
MSN Pharmachem Private Limited₹1,716.51 Cr (FY 2024)40.0%Hyderabad, Telangana, India
Indoco Remedies Limited₹1,670.37 Cr (FY 2025)-9.0%Mumbai, Maharashtra, India
Dishman Pharmaceuticals and Chemicals Limited₹1,622.59 Cr (FY 2016)-3.0%Ahmedabad, Gujarat, India
Indian Immunologicals Limited₹1,512.93 Cr (FY 2025)8.0%Hyderabad, Telangana, India
Virchow Petrochemical Private Limited₹1,499.36 Cr (FY 2025)-7.0%Patancheru, Telangana, India
Neuland Laboratories Ltd.₹1,497.35 Cr (FY 2025)-5.0%Hyderabad, Telangana, India
Viyash Life Sciences Private Limited₹1,482.68 Cr (FY 2025)9.0%Hyderabad, Telangana, India

To see the full peer comparison of Viyash Scientific Limited, buy the company report.

Auditor

Viyash Scientific Limited is audited by S R B C & CO LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
S R B C & CO LLPFY 2023324982E/E300003

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 61.30%, foreign institutional investors hold 4.50%, domestic institutional investors hold 3.80% and retail and other public shareholders hold 30.40%.

Promoters: 61.30%DII (Domestic Institutional): 3.80%FII (Foreign Institutional): 4.50%Retail & Others: 30.40%
Sep 2026
QUARTER
61.30% Promoters
3.80% DII (Domestic Institutional)
4.50% FII (Foreign Institutional)
30.40% Retail & Others
Promoter holding - history
Now 61.30% · Sep 2026High 61.40% · Mar 2026Low 52.30% · Dec 2025
51%54%57%60%63%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 52.30%Mar 2026: 61.40%Jun 2026: 61.30%Sep 2026: 61.30%61.40%52.30%61.30%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters61.30%61.30%61.40%52.30%
Public38.70%38.70%38.60%47.70%

Charges & borrowings

Open charges
₹792.53 Cr
Satisfied charges
₹1,664.02 Cr
Breakdown by lending institutions
Others₹700.41 Cr
Hdfc Bank Limited₹92.12 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
27 Oct 2025101188521Hdfc Bank Limited₹38.92 LakhOpen
04 Oct 2025101169395Hdfc Bank Limited₹38.92 LakhOpen
25 Sep 2025101177637Hdfc Bank Limited₹17.54 LakhOpen
24 Sep 2025101177005Hdfc Bank Limited₹16.53 LakhOpen
05 Mar 2025101082051Hdfc Bank Limited₹24.64 LakhOpen

To see the full charge records of Viyash Scientific Limited, buy the company report.

Total charge records: 68 View all charges

Credit ratings & regulatory alerts

Viyash Scientific Limited was last rated by Icra on 27 Jun 2019.

Rating agencyRated onRating
Icra27 Jun 2019

To see the full credit ratings and regulatory alerts of Viyash Scientific Limited, buy the company report.

MSME payment delays

Viyash Scientific Limited has 10 MSME Form 1 returns on record between 2019 and 2023, listing 676 overdue payments to 113 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 113)

SupplierAmount dueDue sinceReported on
an individual supplier
Sukha Chemical Industries
Godavari Plasto Containers Private Limited
Magnum Cargo Private Limited
Cargo Placement Services and Agencies Private Limited

To see the full MSME payment records of Viyash Scientific Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Viyash Scientific has 7 subsidiary companies. This group structure data is as of FY 2016. The table lists each entity with its relationship and holding.

7
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Sequent Anti Biotics Private LimitedU24230KA2010PTC053487
Sequent Pharmaceuticals Private LimitedU24230KA2010PTC053584
Sequent Research LimitedU24232KA2007PLC042483
Elysian Life Sciences Private LimitedU24232KA2010PTC052742
Sequent Penems Private LimitedU24233KA2010PTC053548
Alivira Animal Health LimitedU74120MH2013PLC248708

To see the full group structure of Viyash Scientific Limited, buy the company report.

Employees & EPFO

Viyash Scientific Limited has a workforce of 399 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.

Employee count
399
Active EPFO establishments
1
Employee growth
-21.15%

GST

Viyash Scientific has 7 GST registrations: 1 active and 6 cancelled or inactive.

Total GSTINs
7
Active
1
Cancelled / inactive
6
GSTINStateStatusRegistered on
29AAACV1501G1ZPKarnatakaActive01 Jul 2017

To see the full GST registrations and return filing status of Viyash Scientific Limited, buy the company report.

Recent activity

Viyash Scientific Limited has 53 board changes on record since 2007: 11 appointments and 42 cessations. The latest: Abhiroop Jayanthi was appointed as Additional Director on 22 Apr 2026.

Appointed
Abhiroop Jayanthi was appointed as Additional Director.
Appointed
Amit Jain was appointed as Additional Director.
Charges
A charge registered on 30 Mar 2021 via Charge ID 100439663 with Hdfc Bank Limited was fully satisfied on 06 Apr 2026.
Filing
Viyash Scientific Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Ceased
Saurav Bhala ceased to be CFO.
Appointed
Hari Babu Bodepudi was appointed as CEO.
Appointed
Srinivas Vasireddy was appointed as Whole-Time Director.
Ceased
Anuj Vishnukumar Poddar ceased to be Additional Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.39 Cr with Charge ID 101188521 was registered on 27 Oct 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.39 Cr with Charge ID 101169395 was registered on 04 Oct 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.18 Cr with Charge ID 101177637 was registered on 25 Sep 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.17 Cr with Charge ID 101177005 was registered on 24 Sep 2025.

179 earlier events are in the company report.

News

Stocks that will see action today: January 22, 2025
22 Jan 2025 · Thehindubusinessline
CAM,
05 Dec 2018 · Legally India

Frequently asked questions

Viyash Scientific is an active public limited company based in Hyderabad, Telangana, India. The company works in pharmaceuticals, within the chemicals industry. It was incorporated on 28 June 1985 (41+ years old) and is registered under CIN L99999TS1985PLC196357. Listed on BSE: 512529 and NSE: VIYASH.

Viyash Scientific reported revenue of ₹3,420.31 Cr for FY 2025-26 (up 13.8% YoY) based on consolidated financials.

Viyash Scientific has 9 current directors and KMP:

The latest financial statements of Viyash Scientific on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 08 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Viyash Scientific is 29AAACV1501G1ZP, registered in Karnataka. The company has 7 GST registrations in all, of which 1 is active and 6 are cancelled or inactive.

The CIN (Corporate Identification Number) of Viyash Scientific is L99999TS1985PLC196357. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Viyash Scientific is a listed company as per MCA records. Its shares are listed on both BSE (code: 512529) and NSE (symbol: VIYASH).

Viyash Scientific has 7 court cases on record: 5 filed by the company and 2 filed against it. Most are in the district courts.

Viyash Scientific was incorporated on 28 June 1985, making it 41+ years old. It is registered with the Registrar of Companies, Hyderabad.

The peers of Viyash Scientific by revenue are Aarti Pharmalabs Limited, Morepen Laboratories Limited, MSN Pharmachem Private Limited, Indoco Remedies Limited, Dishman Pharmaceuticals and Chemicals Limited and 4 more, all in the Pharma industry (API Manufacturers, Animal Pharma), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Abhiroop Jayanthi was appointed as Additional Director on 22 Apr 2026. Amit Jain was appointed as Additional Director on 22 Apr 2026. Saurav Bhala ceased to be CFO on 01 Jan 2026. Viyash Scientific has 53 board changes on record in total.

Viyash Scientific has 10 MSME Form 1 returns on record between 2019 and 2023, listing 676 overdue payments to 113 micro and small suppliers. The latest return was filed on 21 Nov 2023.